Le Lézard
Classified in: Health
Subjects: CSR, FVT

Interview Opportunity: Curiosity Cubetm Arrives in Burlington, Governor Charlie Baker to Attend


BURLINGTON, Mass., Oct. 10, 2017 /PRNewswire/ --

WHO:

MilliporeSigma, a global life science company with its new Greater Boston Hub of approximately 1,300 employees, along with ~50 students from Memorial Elementary School in Burlington, Massachusetts.



WHAT:

MilliporeSigma's Curiosity Cubetm?the latest expansion to its successful Curiosity Labstm concept aiming to reach 350,000 students through a national tour?is making several stops in the Boston area.

 

Attending media can:

  • Tour the Curiosity Cubetm?a 22x10-foot, retrofitted shipping container that has been transformed into a mobile science lab.
  • Record video and take photographs.
  • Learn more about the science lessons, and even find and fix DNA mutations using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).
  • Interview company representatives.

WHEN:

Wednesday, October 11, from 10:45 a.m.- 12:30 p.m. EDT

MilliporeSigma

400 Summit Dr.

Burlington, Massachusetts 01803



WHY:

Hands-on laboratory experiences are critical to sparking student interest in science, technology, engineering and math (STEM) careers. 

 

This key insight is driving a large aspect of MilliporeSigma's corporate responsibility strategy and its investment in Curiosity Labstm. This program has brought interactive, hands-on science lessons and employee volunteers to classrooms around the world to spark scientific curiosity and passion early?paving the way to a future filled with innovative breakthroughs and helping encourage students to pursue careers in STEM fields.

 

MilliporeSigma has also brought its Curiosity Labstm program to Boston Children's Hospital, Boys and Girls Club of Boston, Arthur W. Coolidge Middle School, Boys and Girls Club of Greater Billerica, St. John School, Eugene C. Vining Elementary School and Otho L. Schofield Elementary School.  

 

Learn more about the curiosity concept and how it will continue to grow in the future.

MilliporeSigma employees teach hands-on STEM lessons inside the Curiosity Cubetm

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in health care, life science and performance materials. The company has five businesses? Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials?and generated sales of ?15 billion in 2016. More than 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company?since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

About the Corporate Responsibility Efforts of the Life Science Business of Merck KGaA, Darmstadt, Germany

Through its corporate responsibility initiatives, the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, harnesses the collective expertise, passion and energy of employees to minimize its environmental footprint and positively impact communities around the world.

The Life Science business of Merck KGaA, Darmstadt, Germany is uniquely positioned to solve the toughest problems in life science through its efforts aligned with strengths in research, innovation and collaboration with the global scientific community. This helps differentiate its business and provides a competitive edge for its customers, while accelerating access to health for people everywhere. The Life Science business of Merck KGaA, Darmstadt Germany demonstrates its commitment to corporate responsibility through extensive programs in three main areas: Greener Products and Solutions?which includes Design for Sustainability, Green Chemistry, Packaging and Recycling initiatives; Employee and Community Engagement; and Sustainable Operations.

The Curiosity Cubetmcontinues its year-long tour with several stops in Boston

SOURCE MilliporeSigma


These press releases may also interest you

at 05:50
CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round. The funding has been secured from several new investors;...

at 05:05
Crucial Data Solutions (CDS), a leading provider of data collection and trial management software to advance clinical research, today announced the launch of TrialKit PACS. This innovative solution streamlines medical image management within clinical...

at 05:05
SOPHiA GENETICS , a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDMtm. Syndicate Bio is the...

at 05:00
Bringing order to chaos is a challenge in the best of circumstances. "We support the Ukrainian people in their fight for freedom in a...

at 04:00
Today Benchling announced that Zealand Pharma A/S, ("Zealand") a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data,...

at 03:38
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global...



News published on and distributed by: